1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
02/21/2024 | MED | Buy Now | Medifast | $35.85 | 11.58% | DA Davidson | Linda Bolton Weiser | $67 → $40 | Maintains | Neutral | Get Alert |
10/13/2023 | MED | Buy Now | Medifast | $35.85 | 128.73% | Stephens & Co. | Jim Salera | → $82 | Initiates | → Equal-Weight | Get Alert |
08/08/2023 | MED | Buy Now | Medifast | $35.85 | 123.15% | DA Davidson | Linda Bolton Weiser | $93 → $80 | Maintains | Neutral | Get Alert |
07/31/2023 | MED | Buy Now | Medifast | $35.85 | 159.41% | DA Davidson | Linda Bolton Weiser | $75 → $93 | Maintains | Neutral | Get Alert |
05/02/2023 | MED | Buy Now | Medifast | $35.85 | 98.05% | DA Davidson | Linda Bolton Weiser | $94 → $71 | Maintains | Neutral | Get Alert |
02/22/2023 | MED | Buy Now | Medifast | $35.85 | 162.2% | DA Davidson | Linda Bolton Weiser | $106 → $94 | Maintains | Neutral | Get Alert |
11/04/2022 | MED | Buy Now | Medifast | $35.85 | 195.68% | DA Davidson | Linda Bolton Weiser | $278 → $106 | Downgrade | Buy → Neutral | Get Alert |
08/04/2022 | MED | Buy Now | Medifast | $35.85 | 675.45% | DA Davidson | Linda Bolton Weiser | $352 → $278 | Maintains | Buy | Get Alert |
08/04/2022 | MED | Buy Now | Medifast | $35.85 | 318.41% | Jefferies | Stephanie Wissink | $345 → $150 | Downgrade | Buy → Hold | Get Alert |
06/02/2022 | MED | Buy Now | Medifast | $35.85 | 881.87% | DA Davidson | Linda Bolton Weiser | $341 → $352 | Maintains | Buy | Get Alert |
02/24/2022 | MED | Buy Now | Medifast | $35.85 | 851.19% | DA Davidson | Linda Bolton Weiser | $349 → $341 | Maintains | Buy | Get Alert |
11/08/2021 | MED | Buy Now | Medifast | $35.85 | 873.5% | DA Davidson | Linda Bolton Weiser | — | Maintains | Buy | Get Alert |
05/05/2021 | MED | Buy Now | Medifast | $35.85 | 1001.81% | DA Davidson | Linda Bolton Weiser | — | Maintains | Buy | Get Alert |
The latest price target for Medifast (NYSE: MED) was reported by DA Davidson on February 21, 2024. The analyst firm set a price target for $40.00 expecting MED to rise to within 12 months (a possible 11.58% upside). 5 analyst firms have reported ratings in the last year.
The latest analyst rating for Medifast (NYSE: MED) was provided by DA Davidson, and Medifast maintained their neutral rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medifast, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medifast was filed on February 21, 2024 so you should expect the next rating to be made available sometime around February 21, 2025.
While ratings are subjective and will change, the latest Medifast (MED) rating was a maintained with a price target of $67.00 to $40.00. The current price Medifast (MED) is trading at is $35.85, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.